HomeNewsBusinessCOVID-19 relief package: Mudra-Shishu loan interest subvention scheme brings cheer to microfinance borrowers

COVID-19 relief package: Mudra-Shishu loan interest subvention scheme brings cheer to microfinance borrowers

Announcing the scheme, Sitharaman said the interest subvention scheme will be worth a total of Rs1,500 crore and about three crore people will benefit from this.

May 15, 2020 / 14:15 IST
Story continues below Advertisement
File image
File image

The two percent interest subvention scheme announced by Union Finance Minister Nirmala Sitharaman on Thursday for loans given under the Mudra-Shishu scheme will mainly benefit borrowers of microfinance institutions (MFIs), according to an industry official.

Shishu loans are loans up to Rs 50,000. Announcing the scheme, Sitharaman said the interest subvention scheme will be worth a total of Rs 1,500 crore and about three crore people will benefit from this. Sitharaman said this as part of the second tranche announcements of the government’s Rs 20 lakh crore COVID-19 economic package.

Story continues below Advertisement

According to P Satish, executive director of Sa-Dhan, an industry lobby of microlenders, about half of the Mudra-Shishu loans are given through MFIs. Only a small portion is given through banks.

“As per the latest data available, 45-50 percent of Shishu loans are through MFIs. Borrowers are likely to get benefit of interest subvention amount directly in their bank accounts as per the subvention scheme but details are yet to be finalised,”said Satish.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show